Updated on 2026/06/14

Information

 

写真a

 
IKEMATSU YUKI
 
Organization
Faculty of Medical Sciences Lecturer
Title
Lecturer
External link

Research Areas

  • Life Science / Respiratory medicine

Degree

  • 九州大学大学院医学系学府医学専攻博士課程/医学博士号 （ 2020.3 Kyushu University ）

Education

  • Kyushu University     九州大学大学院医学系学府医学専攻博士課程

    2016.4 - 2020.3

  • Nagasaki University   医学部   医学科

    - 2011.3

Papers

  • Impact of chronic obstructive pulmonary disease on clinical outcomes of EGFR-mutated non–small cell lung cancer patients receiving osimertinib Reviewed

    Chiyo Ishikawa, Yuki Ikematsu, Hiroaki Ogata, Toshifumi Ninomiya, Takahiro Utsumi, Norio Yamamoto, Daisuke Shibahara, Kohei Otsubo, Yoshimasa Shiraishi, Eiji Iwama, Isamu Okamoto

    International Journal of Lung Cancer   2026.6

    　More details

    Authorship：Last author  

  • Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer Reviewed

    Tanaka, K; Chamoto, K; Saeki, S; Hatae, R; Ikematsu, Y; Sakai, K; Ando, N; Sonomura, K; Kojima, S; Taketsuna, M; Kim, YH; Yoshida, H; Ozasa, H; Sakamori, Y; Hirano, T; Matsuda, F; Hirai, T; Nishio, K; Sakagami, T; Fukushima, M; Nakanishi, Y; Honjo, T; Okamoto, I

    SCIENCE TRANSLATIONAL MEDICINE   14 ( 675 )   eabq0021   2022.12   （ ISSN:1946-6234 eISSN:1946-6242 ）

    　More details

    Language：English   Publisher：Science Translational Medicine  

    Despite the success of cancer immunotherapies such as programmed cell death-1 (PD-1) and PD-1 ligand 1 (PDL1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed to overcome this issue. Bezafibrate, a ligand of peroxisome proliferator-activated receptor-γ coactivator 1α/peroxisome proliferator-activated receptor complexes, has shown a synergistic antitumor effect with PD-1 blockade in mice that is mediated by activation of mitochondria in T cells. We have therefore now performed a phase 1 trial (UMIN000017854) of bezafibrate with nivolumab in previously treated patients with advanced non-small cell lung cancer. The primary end point was the percentage of patients who experience dose-limiting toxicity, and this combination regimen was found to be well tolerated. Preplanned comprehensive analysis of plasma metabolites and gene expression in peripheral cytotoxic T cells indicated that bezafibrate promoted T cell function through up-regulation of mitochondrial metabolism including fatty acid oxidation and may thereby have prolonged the duration of response. This combination strategy targeting T cell metabolism thus has the potential to maintain antitumor activity of immune checkpoint inhibitors and warrants further validation.

    DOI： 10.1126/scitranslmed.abq0021

    Web of Science

    Scopus

    PubMed

  • Acute exacerbation in antineutrophil cytoplasmic antibody-associated interstitial lung disease: Clinical features and risk factors. Reviewed

    Junji Otsuka, Shigeru Yoshizawa, Yuki Ikematsu, Kunihiro Kudo, Hisayuki Osoreda, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwak

    Respiratory Medicine   2022.11

    　More details

    Language：English  

  • Small-cell lung cancer from the peripheral lung is frequently accompanied by emphysema and interstitial lung disease in the background Reviewed

    Yuki Ikematsu, Miiru Izumi ,　Koichi Takayama, Hiroyuki Kumazoe , Kentaro Wakamatsu , Masayuki

    Thorac Cancer   2022.9

    　More details

    Authorship：Lead author  

  • Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM 1 receptor Reviewed

    Okamura, K; Inoue, H; Ikematsu, Y; Furukawa, R; Tanaka, K; Okamoto, I

    CANCER SCIENCE   113   580 - 580   2022.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • Cytotoxic chemotherapeutic agents and osimertinib induce calreticulin exposure in non-small cell lung cancer Reviewed

    Furukawa, R; Inoue, H; Ikematsu, Y

    CANCER SCIENCE   113   837 - 837   2022.2   （ ISSN:1347-9032 eISSN:1349-7006 ）

    　More details

  • NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration Reviewed

    Yuki Ikematsu, Kentaro Tanaka, Toyoshi Yanagihara, Renpeng Liu, Hiroyuki Inoue, Yasuto Yoneshima, Keiichi Ota, Eiji Iwama, Shohei Takata, Kentaro Hata, Yuriko Takahata, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2020.8

    　More details

    Language：English  

    DOI： 10.1016/j.lungcan.2020.05.012

  • Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti–PD-1 therapy Reviewed

    Yuki Ikematsu, Kentaro Tanaka, Toyoshi Yanagihara, Renpeng Liu, Hiroyuki Inoue, Yasuto Yoneshima, Keiichi Ota, Eiji Iwama, Shohei Takata, Kentaro Hata, Yuriko Takahata, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2018.12

    　More details

    Authorship：Lead author  

  • Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Reviewed International journal

    Kentaro Tanaka, Toyoshi Yanagihara, Yuki Ikematsu, Hiroyuki Inoue, Keiichi Ota, Eiji Kashiwagi, Kunihiro Suzuki, Naoki Hamada, Ario Takeuchi, Katsunori Tatsugami, Masatoshi Eto, Kayo Ijichi, Yoshinao Oda, Kohei Otsubo, Yasuto Yoneshima, Eiji Iwama, Yoichi Nakanishi, Isamu Okamoto

    2018.7

    　More details

  • Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1 Reviewed

    Yuki Ikematsu, Yasuto Yoneshima, Kayo Ijichi, Kentaro Tanaka, Taishi Harada, Yoshinao Oda, Yoichi Nakanishi, Isamu Okamoto

    LUNG CANCER   2017.11

    　More details

    Authorship：Lead author  

▼display all

Books

  • 私の治療 Reviewed

    池松祐樹, 藤平智道, 岡本勇（Role：Contributor肺癌 (非小細胞肺癌)）

    日本医事新報社  2017.7 

  • 診断と治療のABC123　呼吸器腫瘍 Reviewed

    池松祐樹, 岡本勇（Role：Contributor進行期非小細胞肺がんの薬物療法, 2ドライバー遺伝子変異陽性症例）

    最新医学社  2017.6 

Presentations

▼display all